Author

U. Malapelle

h-index 53 View on Semantic Scholar

We have 5 of 475 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

The Dynamic Role of Liquid Biopsy in Patients with Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: Emerging Opportunities and Clinical Challenges

Simple Summary Immunotherapy has improved outcomes for people with non-small-cell lung cancer, but some patients do not benefit or develop resistance during treatment. Blood tests known as liquid biopsies may help monitor cancer by detecting tumor-derived DNA and other circulating signals. This review examines their po...

T. D. Bazan Russo, V. Gristina, F. Pepe et al. · Cancers · 0 citations

Open access Sep 2026

Minimal residual disease combined with radiological tumor volume as a tool for identification of resected NSCLC patients at high risk of recurrence

Introduction Circulating tumor DNA (ctDNA) is a valuable tool for assessing minimal residual disease (MRD) and predicting recurrence in resected non-small cell lung cancer (NSCLC) patients. Combining ctDNA-detection with radiological tumor volume may improve risk stratification. Methods Patients with stage I-III resect...

M. Verzè, R. Minari, P. Bordi et al. · The journal of liquid biopsy · 0 citations

Open access Aug 2026

Design and analytical validation of Nexthyro 2.0, a custom next-generation sequencing panel integrating DNA mutation profiling and RNA fusion detection for routine thyroid pathology specimens.

Nexthyro 2.0 represents a reliable local solution for thyroid molecular testing across cytological and histological specimens encountered in routine clinical practice and is validated as a locally deployable alternative to centralized tests.

M. Nacchio, A. M. Carillo, D. Di Giovanni et al. · Virchows Archiv · 0 citations

Review Open access Aug 2026

Epigenetic profiling of circulating cell-free DNA for early detection and minimal residual disease assessment in lung cancer: a focus on DNA methylation

The biological and clinical relevance of the epigenetic landscape of cfDNA in LC patients is explored, particularly focusing on DNA methylation-based biomarkers and their evolving applications towards early diagnosis and post-surgical monitoring of minimal residual disease (MRD).

T. D. Bazan Russo, V. Gristina, M. D. Delcuratolo et al. · Frontiers in Oncology · 0 citations

Review Open access Sep 2026

Liquid biopsy: a new window on the BRCA genes

Beyond the attractive potential to surrogate the tumor tissue testing, to overcome the cancer spatial and temporal heterogeneity, and to monitor the tumor mutational profile over time, accurately detecting all clinically relevant BRCA genetic variants and epigenetic modifications using LB remains technically challengin...

L. Incorvaia, V. Gristina, F. Pepe et al. · ESMO Open · 0 citations